BioMarin's Carnage Could Be Buying Opportunity, Says Stifel By: Benzinga via Benzinga February 16, 2016 at 11:06 AM EST According to a recent research summary from Stifel, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is deserving of an ... Read More >> Related Stocks: Biomarin Pharmaceuticals